VONPRAN is an innovative potassium-competitive acid blocker (P-CAB). Unlike traditional proton pump inhibitors, vonoprazan provides faster onset of action and more consistent acid suppression regardless of food intake.
Mechanism of action:
Vonoprazan inhibits the H+/K+-ATPase enzyme in gastric parietal cells, blocking the final step of acid secretion. This allows effective mucosal healing and symptom relief.
Recommended for:
Clinical studies demonstrate that vonoprazan achieves and maintains intragastric pH above 4 more rapidly and consistently compared to conventional PPIs such as omeprazole. Research in Japan and other countries confirms its high eradication rates in H. pylori therapy, including resistant strains.
Indicated for the treatment of GERD, erosive esophagitis, gastric and duodenal ulcers, and prevention of ulcer recurrence. Used in combination therapy for Helicobacter pylori eradication. Works by suppressing excessive gastric acid secretion.
Take orally with water. Dosage and duration depend on diagnosis and severity and must be determined by a healthcare provider. May be used alone or in combination therapy.
Contraindications
Side Effects
